The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide ID: ALA4476642
PubChem CID: 155538637
Max Phase: Preclinical
Molecular Formula: C19H28N4O2
Molecular Weight: 344.46
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: CCCCCn1cc(C(=O)N[C@H](C(N)=O)C(C)(C)C)c2cccnc21
Standard InChI: InChI=1S/C19H28N4O2/c1-5-6-7-11-23-12-14(13-9-8-10-21-17(13)23)18(25)22-15(16(20)24)19(2,3)4/h8-10,12,15H,5-7,11H2,1-4H3,(H2,20,24)(H,22,25)/t15-/m1/s1
Standard InChI Key: QDZHLYBDQFZWCJ-OAHLLOKOSA-N
Molfile:
RDKit 2D
25 26 0 0 0 0 0 0 0 0999 V2000
7.3712 -22.4934 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.6568 -22.0852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6517 -21.2639 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.9476 -22.5024 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.0650 -23.4956 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.8673 -23.3205 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1946 -22.1735 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.9384 -21.3972 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.1359 -21.2324 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5900 -21.8501 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7374 -24.2483 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9211 -24.3390 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5894 -25.0918 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7731 -25.1824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.4455 -25.9352 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0771 -22.0817 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7866 -22.4871 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7903 -23.3043 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.0735 -21.2645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.7794 -20.8527 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3640 -20.8590 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.4925 -22.0754 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.0687 -20.4463 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8497 -22.6250 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.6506 -22.7875 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
2 4 1 0
4 7 1 0
25 5 1 0
5 6 1 0
6 4 2 0
25 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
5 11 1 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
1 16 1 0
16 17 1 0
17 18 2 0
16 19 1 1
19 20 1 0
19 21 1 0
17 22 1 0
19 23 1 0
10 24 2 0
24 25 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 344.46Molecular Weight (Monoisotopic): 344.2212AlogP: 2.86#Rotatable Bonds: 7Polar Surface Area: 90.01Molecular Species: NEUTRALHBA: 4HBD: 2#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 3.12CX LogP: 2.79CX LogD: 2.79Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.76Np Likeness Score: -0.81
References 1. Moir M, Lane S, Lai F, Connor M, Hibbs DE, Kassiou M.. (2019) Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids., 180 [PMID:31319265 ] [10.1016/j.ejmech.2019.07.036 ] 2. Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, Deventer MH, Ellison R, Boyd R, Martin LJ, McGregor IS, Gerona RR, Hibbs DE, Auwärter V, Glass M, Stove C, Banister SD.. (2022) Structure-activity relationships of valine, tert -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA., 13 (2.0): [PMID:35308023 ] [10.1039/d1md00242b ]